AKEBIA THERAPEUTICS, INC. Derivative Liability
AKEBIA THERAPEUTICS, INC. (AKBA) had Derivative Liability of $1.96 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:DerivativeLiabilities · last filed 2026-08-05
- 2026-06-30: Derivative Liability $1.96M.
- 2026-03-31: Derivative Liability $2.52M.
- 2025-12-31: Derivative Liability $2.98M.
- 2025-09-30: Derivative Liability $5.20M.
| Period end | Derivative Liability | Derivative Liability as first filed |
|---|---|---|
| 2026-06-30 | $1.96M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $2.52M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $2.98M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $5.20M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $14.20M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $7.20M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $5.18M 10-K · filed 2026-02-26 | $5.20M 10-K · filed 2025-03-13 |
| 2024-09-30 | $3.50M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $2.60M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $5.00M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $0.00 10-K · filed 2024-03-14 | |
| 2023-09-30 | $760.00K 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $760.00K 10-Q · filed 2023-08-28 | |
| 2023-03-31 | $760.00K 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $760.00K 10-K · filed 2024-03-14 | |
| 2022-09-30 | $760.00K 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $1.11M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $1.11M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $1.82M 10-K/A · filed 2023-08-28 | |
| 2021-09-30 | $1.93M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $1.93M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $2.50M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $2.42M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $1.99M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $1.89M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $1.74M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $1.65M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |